<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Synthesis, Characterization and Cytotoxic Effect of a Novel Quinone-based Compound for Cholangiocarcinoma: a Promising Proapoptotic Agent Through Mitochondria

dc.contributor.authorBulut, Gizem
dc.contributor.authorKayis, Merve
dc.contributor.authorOzyildiz, Zeynep
dc.contributor.authorGokmen, Zeliha
dc.contributor.authorAdiguzel, Zelal
dc.contributor.authorRaggi, Chiara
dc.contributor.authorUlukaya, Engin
dc.date.accessioned2026-11-05T11:00:58Z
dc.date.issued2026
dc.description.abstractCholangiocarcinoma patients remain in need of novel therapeutic options due to poor survival. Therefore, a new naphthoquinone derivative, ZP-4, was explored for its cytotoxic potential on CCA cell lines CCLP1 and HUCCT1 after its synthesis and structural characterization. ZP-4 exerted dose-dependent antiproliferative and cytotoxic effects in both cell lines, with CCLP1 cells displaying greater sensitivity than HUCCT1 cells. The reduction in cell viability was accompanied by apoptotic cell death evidenced by pyknotic nuclei and phosphatidylserine translocation. Flow cytometric analyses revealed increased oxidative stress and DNA damage following ZP-4 treatment, supporting a potential association of these cellular responses with the observed apoptotic phenotype. qPCR analysis revealed the upregulation of the pro-apoptotic gene HRK, the stress-responsive gene GADD45A, and the mitophagy-associated gene BNIP3L, further supporting the induction of cellular stress responses by ZP-4. Collectively, these findings identify ZP-4 as a promising candidate for cholangiocarcinoma therapy and support further preclinical evaluation in animal models.
dc.description.sponsorshipThis publication is based upon work from the European Network for the Study of Cholangiocarcinoma and the COST Action Precision-BTC-Network CA22125, supported by COST (European Cooperation in Science and Technology; www.cost.eu). The ZP-4 compound has been submitted to Turkish Patent and Trademark Office (TURKPATENT) under the patent application number TR2022/015926. This study was funded by the Scientific Research Projects Coordination Unit of Istanbul University-Cerrahpa & scedil;a (Project numbers: FBA-2024-37858).
dc.identifier.doi10.1007/s44411-026-00848-z
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.urihttps://doi.org/10.1007/s44411-026-00848-z
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10612
dc.identifier.wosWOS:001871930400001
dc.language.isoen
dc.publisherSPRINGERNATURE
dc.relation.fundingIstanbul niversitesi-Cerrahpasa
dc.relation.fundingIstanbul niversitesi-Cerrahpasa [FBA-2024-37858]
dc.relation.hasversion10.1007/s44411-026-00848-z
dc.relation.ispartofBRATISLAVA MEDICAL JOURNAL
dc.subjectQuinone
dc.subjectAnticancer drug
dc.subjectBiliary tract
dc.subjectCell death
dc.subjectChemotherapy
dc.subjectMUTANT P53
dc.subjectCANCER
dc.subjectAPOPTOSIS
dc.subjectDEATH
dc.subjectGAIN
dc.subjectMedicine, General & Internal
dc.subjectGeneral & Internal Medicine
dc.titleSynthesis, Characterization and Cytotoxic Effect of a Novel Quinone-based Compound for Cholangiocarcinoma: a Promising Proapoptotic Agent Through Mitochondria
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
person.identifier.ridK-5792-2018
person.identifier.ridU-3081-2017
person.identifier.ridNYS-8597-2025

Files

Collections